title: The XRCC1 -77T->C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage.
abstract: X-ray repair cross-complementing 1 (XRCC1) is required for single-strand break repair in human cells and several polymorphisms in this gene have been implicated in cancer risk and clinical prognostic factors. We examined the frequency of the 5'-untranslated region (5'-UTR) variant -77T-->C (rs 3213235) in 247 French breast cancer (BC) patients, 66 of whom were adverse radiotherapy responders, and 380 controls and determined the haplotypes based on this and the previously genotyped variants Arg194Trp, Arg280His and Arg399Gln. The -77T-->C variant alone showed no significant association with BC risk or therapeutic radiation sensitivity. The H5 haplotype (variant allele codon 280, wild-type allele other positions) was associated with increased BC risk [odds ratio (OR), 1.90; 95% confidence interval (CI), 1.12-3.23] and the H3 haplotype (wild-type allele all four positions) was inversely associated with therapeutic radiation sensitivity compared with the reference group (H1 haplotype, -77C, wild-type allele codons 194, 280, 399) (OR, 0.39; 95% CI, 0.16-0.92). However given that the global tests for association were not significant these results should be interpreted carefully. Lymphoblastoid cell lines heterozygous for the H1/H3 haplotypes had a significantly higher cell survival (P=0.04) after exposure to ionising radiation (IR) than those with the H1/H1 haplotypes, in agreement with the association study. However no haplotype-specific differences in XRCC1 expression or cell cycle progression were noted in the 24 h following IR exposure. These results suggest that the -77T-->C genotype or another variant in linkage disequilibrium influences the cellular response to DNA damage, although the underlying molecular mechanisms remain to be established.
authors.affiliation: International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France.
authors.forename: Reto
authors.initials: R
authors.lastname: Brem
authors.forename: David G
authors.initials: DG
authors.lastname: Cox
authors.forename: Brigitte
authors.initials: B
authors.lastname: Chapot
authors.forename: Norman
authors.initials: N
authors.lastname: Moullan
authors.forename: Pascale
authors.initials: P
authors.lastname: Romestaing
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Gérard
authors.forename: Paola
authors.initials: P
authors.lastname: Pisani
authors.forename: Janet
authors.initials: J
authors.lastname: Hall
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D002453:Cell Cycle; D002470:Cell Survival; D004249:DNA Damage; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D014644:Genetic Variation; D006801:Humans; D015810:Linkage Disequilibrium; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D000076105:X-ray Repair Cross Complementing Protein 1
chemical_list: D004268:DNA-Binding Proteins; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human